Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARGARET phase I/II study of TAS0953/HM06 in RET-altered advanced solid tumors
jRCT2031200208Phase 2Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of vepafestinib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (8 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Feb 2021; status: recruiting.
02
Drugs
vepafestinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031200208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200208.